Clinical trials led by UCLA Health’s Jonsson Comprehensive Cancer Center demonstrate that combining PSMA-targeted radioligand therapy with stereotactic body radiotherapy more than doubles progression-free survival in men with recurrent prostate cancer compared to radiation alone. This Phase II study, known as LUNAR, marks a pivotal advancement in managing oligometastatic prostate cancer and paves the way for new multimodal treatment approaches.